MEDOVATE SECURES LICENCE TO DEVELOP AND LAUNCH GROUND-BREAKING ANAESTHESIA INNOVATIONS

Medovate, the medical device company dedicated to the development and commercialisation of medical technologies, has today announced that it has secured the exclusive rights to design, develop, manufacture and sell two ground-breaking innovations in the field of anaesthesia.

The innovations in question are Regional Anaesthesia Device (RADS), developed with Leeds Teaching Hospitals NHS Trust, and the Safer Injection For Regional Anaesthesia (SAFIRA) which is being developed with The Queen Elizabeth Hospital, Kings Lynn, NHS Foundation Trust. Both innovations have been invented by leading Anaesthetists working at their respective NHS Trusts.

Medovate was launched by Health Enterprise East (HEE), the NHS innovation hub, in February 2018 with investment capital worth £9m and a remit to boost the financial and technical support available to medtech innovators within the NHS. RADS and SAFIRA are the first products to be added to Medovate’s portfolio, and under the terms of the licence agreements, Medovate can now take these innovations through the phases of design & development, regulatory approval and clinical trial to market launch.

RADS and SAFIRA are complementary local anaesthesia products designed to ensure that regional blocks are delivered within safe pressure limits. RADS is an easily portable product, making it ideal for use one operator.

SAFIRA provides an end-to-end safety solution and gives anaesthetists enhanced data monitoring, recording the entire procedure with precise readings on time, pressure and volume to provide safe anaesthetic administration.

Stuart Thomson, Managing Director of Medovate, commented: “There are approximately 6 million regional block procedures carried out in the EU and US each year. Injection above the published safe pressure threshold can lead to serious nerve damage in up to 1% of cases and transient nerve damage in up to 5% cases, so this is a major problem. There are also broader repercussions including financial compensation claims, increased anaesthetist and care provider anxiety and importantly, a rise in patient re-admission. RADS and SAFIRA together can tackle all these problems and help ensure that complications from nerve damage finally become a thing of the past.”

Anne Blackwood, CEO of Health Enterprise East, commented: “RADS and SAFIRA are fantastic examples of the many innovative ideas being developed by NHS staff in hospitals all around the UK. We are proud to have been involved in the formation of Medovate and their technical and commercial expertise will help to fast-track innovations of this kind. We look forward to seeing both patients and clinicians reaping the benefits once RADS and SAFIRA come to market.”